Clinical exploration of enzalumide as first-line neoadjuvant therapy for metastatic hormone sensitive prostate cancer
10.3760/cma.j.cn112330-20210908-00016
- VernacularTitle:转移性激素敏感性前列腺癌应用恩扎卢胺一线新辅助治疗的临床探索
- Author:
Zengshu XING
1
;
Zhenxiang LIU
;
Zhiming BAI
Author Information
1. 中南大学湘雅医学院附属海口医院泌尿外科，海口 570208
- Keywords:
Prostate cancer;
Enzalutamide;
Neoadjuvant hormonal therapy
- From:
Chinese Journal of Urology
2021;42(Z2):54-56
- CountryChina
- Language:Chinese
-
Abstract:
Enzalumide has not been approved for therapy in metastatic hormone sensitive prostate cancer (mHSPC) patients in China. This study retrospectively analyzed the response to treatment of Enzalutamide as first-line neoadjuvant hormonal therapy for mHSPC. A 69-year-old man with prostate cancer characterized with clinical staging T 3bN 1M 1b, tPSA 240.69ng/ml and Gleason score 8, was administrated with Enzalumide as neoadjuvant hormonal therapy for 6 months. Re-examination for prostate MRI indicated the prostate, tumor lesion and the enlarged lymph nodes in the pelvic cavity were significantly smaller than before. Therefore, a robot-assisted laparoscopic radical prostatectomy was performed. Postoperative pathology showed resection margins were negative and no metastasis was observed in lymph nodes of pelvic cavity. After the operation, adjuvant hormonal therapy was performed. Blood tPSA was 0.016ng/ml at 6 weeks, and no tumor recurrence or enlarged lymph nodes were found in pelvic MRI at 6 months. Therefore, in this case, Enzalutamide as first-line neoadjuvant hormonal therapy can reduce the clinical staging of mHSPC, which may allow surgical resection of the tumor.
